Details:
AVT04 (ustekinumab) is a monoclonal antibody and a biosimilar candidate to Stelara® (ustekinumab). Ustekinumab binds to two cytokines, IL-12 and IL-23, that are involved in inflammatory and immune responses.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: AVT04
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
Simlandi (adalimumab) is a monoclonal antibody which inhibits tumor necrosis factor. It binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Simlandi
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
AVT02 is a monoclonal antibody and has been approved as a biosimilar to Humira® (adalimumab) in the 27 EU member countries. FDA has completed review of Alvotech’s application of AVT02 as an interchangeable to high-concentration of Humira®.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: AVT02
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
Hukyndra (adalimumab) is a monoclonal antibody and a biosimilar to Humira® (adalimumab) that inhibits tumor necrosis factor. Adalimumab is first product launched through an exclusive strategic partnership announced by Alvotech and STADA in November 2019.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Hukyndra
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: STADA Arzneimittel
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
AVT02 / Ciptunec™ / Ardalicip™ (adalimumab), is a monoclonal antibody and approved biosimilar to Humira® (adalimumab), which inhibits tumor necrosis factor for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: AVT02
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
AVT02 is a monoclonal antibody that is being evaluated for biosimilarity and interchangeability to Humira® (adalimumab), which inhibits tumor necrosis factor (TNF).
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: AVT02
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
The biosimilar to Humira®, with its 100 mg/mL Hukyndra (adalimumab) in 40 mg/0.4 mL custom-designed pre-filled auto-injector pen as well as 40 mg/0.4 mL and 80 mg/0.8 mL pre-filled syringe presentations, offers a comprehensive range of biosimilar and devices designed.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Hukyndra
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: STADA Arzneimittel
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
AVT02 monoclonal antibody is a high concentration biosimilar to adalimumab (Humira®) approved by EU used to treat a range of certain inflammatory conditions.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: AVT02
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2021